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Abstract
Background: The prognosis for patients with advanced FIGO stage III epithelial ovarian cancer remains poor
despite the aggressive standard treatment, consisting of maximal cytoreductive surgery and platinum-based
chemotherapy. The median time to recurrence is less than 2 years, with a 5-years survival rate of -20-25%.
Recurrences of the disease occur mostly intraperitoneally.
Ovarian cancer is a radiosensitive tumor, so that the use of whole abdominal radiotherapy (WAR) as a
consolidation therapy would appear to be a logical strategy. WAR used to be the standard treatment after surgery
before the chemotherapy era; however, it has been almost totally excluded from the treatment of ovarian cancer
during the past decade because of its high toxicity. Modern intensity-modulated radiation therapy (IMRT) has the
potential of sparing organs at risk like kidneys, liver, and bone marrow while still adequately covering the
peritoneal cavity with a homogenous dose.
Our previous phase I study showed for the first time the clinical feasibility of intensity-modulated WAR and pointed
out promising results concerning treatment tolerance. The current phase-II study succeeds to the phase-I study to
further evaluate the toxicity of this new treatment.
Methods/design: The OVAR-IMRT-02 study is a single-center one arm phase-II trial. Thirty seven patients with
optimally debulked ovarian cancer stage FIGO III having a complete remission after chemotherapy will be treated
with intensity-modulated WAR as a consolidation therapy.
A total dose of 30 Gy in 20 fractions of 1.5 Gy will be applied to the entire peritoneal cavity including the liver
surface and the pelvic and para-aortic node regions. Organ at risk are kidneys, liver (except the 1 cm-outer border),
heart, vertebral bodies and pelvic bones.
Primary endpoint is tolerability; secondary objectives are toxicity, quality of life, progression-free and overall survival.
Discussion: Intensity-modulated WAR provides a new promising option in the consolidation treatment of ovarian
carcinoma in patients with a complete pathologic remission after adjuvant chemotherapy. Further consequent
studies will be needed to enable firm conclusions regarding the value of consolidation radiotherapy within the
multimodal treatment of advanced ovarian cancer.
Trial registration: Clinicaltrials.gov: NCT01180504
* Correspondence: nathalie.rochet@med.uni-heidelberg.de
1Department of Radiation Oncology, University of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
Rochet et al. BMC Cancer 2011, 11:41
http://www.biomedcentral.com/1471-2407/11/41
© 2011 Rochet et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Ovarian cancer has the highest mortality rate of all
gynaecologic cancer in the western world. Symptoms
tend to be vague; hence the disease is often detected
late. 75% of patients present with advanced stage dis-
ease, after it has spread into the peritoneal cavity (stage
FIGO III). Despite the aggressiveness of the current
standard treatment, consisting in maximal cytoreductive
surgery and adjuvant combination chemotherapy (carbo-
platin and taxane), the prognosis for patients in a stage
FIGO III disease remains poor. The median time to
recurrence is less than 2 years. Typically recurrences
occur intraperitoneally, distant metastasis appear mostly
later in the course of the disease. The 5-year survival
rate for stage FIGO III disease is approximately 20-25%
[1-5]. Various sorts of consolidation therapy have been
studied in a series of clinical trials, but yet none has
shown to improve survival in ovarian cancer [6-8].
The use of whole abdominal radiotherapy (WAR) as a
consolidation therapy would appear to be a logical strategy
given that ovarian cancer is a radiosensitive tumor. The
fact that WAR can be curative in certain groups of
patients has been shown by intensive studies by Dembo et
al [9,10]. However, the role of radiation therapy in ovarian
cancer remains controversial. In the 1950s, surgery and
adjuvant WAR were the dominant treatment modalities
[9,10]. Since the improvements of chemotherapy, which
gives primarily high response rates and has a systemic
effect, radiotherapy has been increasingly abandoned [11].
WAR as a consolidation concept after surgery and
chemotherapy has been evaluated in a number of small
and non-randomized studies with contradictory results
[12-17]. The recent randomized trial of Sorbe indicated
that WAR may have a place in the treatment of
advanced ovarian carcinoma in patients with complete
pathologic remission after adjuvant chemotherapy [18].
A potential benefit was noted regarding the rate of
recurrence and progression-free as well as overall survi-
val rates. These results are supported by other small
recent series [15,19-23]. It seems that 30 Gy delivered to
the whole abdomen can eliminate residual microscopic
disease in 45-50% of the cases [15].
However, there are many reasons why consolidation
WAR fell into disfavour. It is associated with a high rate
of severe acute side effects, particularly myelosuppres-
sion, due to additive toxicities after chemotherapy,
which often leads to delayed or incomplete radiotherapy
[16]. WAR is ineffective for patients with macroscopic
disease residuum after chemotherapy [24]. Using the
conventional technique, WAR is not able to deliver ade-
quate radiation doses to the upper abdomen, due to lim-
iting organs at risk (OAR), especially liver and kidneys
[9]. Eventually WAR is unpopular because of the late
bowel toxicity, which is surgically difficult to manage.
As a consequence, during the past decade, WAR has
been almost totally excluded from the treatment of
advanced ovarian. However, toxicity can now be managed
by modern radiotherapy techniques using intensity-modu-
lated radiotherapy (IMRT), which allow a very precise irra-
diation of complex target volumes while sparing organs at
risk like kidneys, liver, and bone marrow [25-29].
Our previous phase I study showed, for the first time,
the clinical feasibility of intensity-modulated WAR in
combination with modern chemotherapy and surgery
and pointed out promising results concerning treatment
tolerance [26,30,31]. Ten patients with optimally
debulked ovarian cancer FIGO stage IIIc were treated
with intensity-modulated WAR up to a total dose of
30 Gy in 1.5 Gy fractions as a consolidation therapy
after adjuvant carboplatin/taxane chemotherapy. Treat-
ment was delivered using IMRT in step-and-shoot tech-
nique (n = 3) or helical tomotherapy technique (n = 7).
The planning target volume (PTV) included the entire
peritoneal cavity and the pelvic and para-aortic node
regions. Organs at risk (OARs) were kidneys, liver,
heart, vertebral bodies and pelvic bones.
Intensity-modulated WAR rendered an excellent cover-
age of the entire peritoneal cavity including frequent sites
of abdominal recurrence like the liver capsule and the dia-
phragm as well as of the pelvic- and para-aortic node
regions. An effective sparing of liver, kidneys and bone
marrow allowed delivering the treatment as planned, with
a high compliance of patients. Radiotherapy was well toler-
ated, no severe acute side effects CTC grade 4 occurred.
CTC grade 3 toxicities were: diarrhea (n = 1), thrombocy-
topenia (n = 1) and leukopenia (n = 3). After a median fol-
low-up of 23 months, 4 patients had a tumor recurrence
(intraperitoneal progression n = 3, hepatic metastasis
n = 1). Small bowel obstruction due to adhesions occurred
in 3 patients, 2.5, 3 and 13 months respectively after
radiotherapy.
We initiated the current phase-II study to further
evaluate toxicity and outcome of intensity-modulated
whole-abdominal radiotherapy. The primary objective of
the OVAR-IMRT-02 trial is to demonstrate the good
tolerability this intensive multimodal adjuvant treatment
in a cohort of 37 patients with advanced ovarian-cancer
FIGO stage III, optimally debulked and with a complete
remission after chemotherapy. Secondary objectives are
rate of therapy stop, rate of therapy interruption, rate of
acute toxicity, rate of late toxicity, rate of relapse-free
survival, rate of overall-survival and quality of life
(EORTC-QLQ30).
Methods/design
Study design
The OVAR-IMRT-02 is designed as a single-center one
arm prospective phase II trial. In order to accelerate the
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center. Patients fulfilling the inclusion criteria will be
treated with intensity-modulated WAR up to a total
dose of 30 Gy in 1.5 Gy fractions within a consolidation
concept. Thirty seven patients are planned to be
enrolled.
Study objectives
The aim of the study is to demonstrate superior toler-
ability of consolidating intensity-modulated WAR com-
pared to the conventional technique.
To get an impression of the tolerability of current
radiation approaches, we explored the results from his-
torical data on conventional radiation procedure. Adju-
vant WAR using the conventional technique after
radical surgery and chemotherapy showed a high rate of
acute side effects (especially hematotoxicity, but also
nausea, vomiting and diarrhoe). The pronounced acute
toxicity, which is described in the literature as “severe”,
leads in many cases to a stop (10-15%) or to an inter-
ruption (15-30%) of the therapy and with it to a reduc-
tion of its efficacy [22,23,32,33]. This is one of the
reasons why WAR is no longer applied. Within the
OVAR-IMRT-01 Study, none of the 10 patients showed
an acute toxicity CTC grade 4 (0%), and the CTC grade
3 toxicity rate was 40%.
Primary outcome variable of the OVAR-IMRT-02
Study is the tolerability of therapy, defined by the non-
occurrence of CTC grade 4 toxicity during the radiation
therapy and until 6 weeks after its termination.
Secondary outcome variables are the rate of therapy
stop, rate of therapy interruption, rate of acute toxicity,
rate of late toxicity, rate of relapse-free survival, rate of
overall survival and quality of life (EORTC-QLQ30).
Trial organisation
The trial OVAR-IMRT-02 is an investigator initiated
trial. The trial is carried out by the Department of
Radiation Oncology at the University of Heidelberg in
co-operation with the Department of Gynaecology and
Obstetrics. Statistical analysis and data management are
performed by the Institute of Medical Biometry and
Informatics at the University of Heidelberg. The trial is
partly financially supported by the German Cancer Aid
(Deutsche Krebshilfe).
Coordination
The overall coordination is performed by the Department
of Radiation Oncology at the University of Heidelberg.
Patient selection: Inclusion criteria
Patients meeting all the following criteria will be consid-
ered for admission to the trial:
￿ histologically confirmed ovarian cancer or tube
cancer or primary peritoneal carcinoma stage FIGO
III
￿ status post primary optimal debulking surgery
￿ postoperative gross residual tumor ≤ 1c m( R 0 ,R 1
or R2 < 1 cm situation)
￿ status post (neo-) adjuvant chemotherapy with
platin and taxane
￿ complete remission after adjuvant chemotherapy
(clinically, radiographically and biochemically)
￿ Karnofsky performance score > 60
￿ patient >18 years of age
￿ written informed consent
Patient selection: Exclusion criteria
￿ stage FIGO I or II
￿ stage III with postoperative gross residual tumor >
1cm
￿ stage FIGO IV
￿ recurrence situation
￿ delayed wound healing post laparotomy
￿ leucopenia <2000/ml before radiotherapy
￿ thrombocytopenia <75000/ml before radiotherapy
￿ clinically active renal, hepatic, cardiac, metabolic,
respiratory, coagulation or hematopoietic disease
￿ status post pelvic or abdominal radiotherapy
￿ status post other cancer disease in the past 5 years
(cervical cancer in situ, basal cell carcinoma, squa-
mous cell carcinoma of the skin are excluded)
￿ participation in another clinical trial
Statistical Design and Methods
The primary endpoint of the trial is the tolerability rate,
which is calculated as the percentage of patients for
which no CTC Grade 4 toxicity occurs during the radia-
tion therapy and until 6 weeks after its termination. The
target tolerability rate is 90%, and a tolerability rate of
less or equal to 70% is considered to be not of interest.
Denoting the tolerance rate by p, the related test pro-
blem can be formulated as H0: p ≤ p0 = 0.70 versus H1:
p ≥ p1 = 0.90 which will be assessed at one-side signifi-
cance level a = 0.05.
The trial is designed as a two-stage study with a
planned interim analysis, allowing for early stopping,
and a power of 0.90 to reject the null hypothesis. In the
first stage, 15 patients are enrolled. If all these patients
would tolerate radiation therapy according to the defini-
tion of the primary endpoint, the study would stop with
rejection of the null hypothesis. The study would termi-
nate with acceptance of the null hypothesis, if less than
12 of the first 15 patients would tolerate the radiation
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continue with the second stage enrolling further
22 patients, if the number of patients that tolerate radia-
tion therapy is between 12 and 14. In the final analysis,
the null hypothesis can be rejected if the product of the
one-sided p-values of the two stages is lower or equal to
0.021. With an expected sample size of 21.4 for a toler-
ability rate of p0 = 0.70 (i.e., under the null hypothesis),
this design shows similar characteristics as Simon’s
(1989) optimal design whose expected sample size is
21.2. under the same scenario [34]. However, the adap-
tive two-stage design implemented in this trial allows a
data-driven modification of the sample size of the sec-
ond stage based on the results of the interim analysis or
on external information while the specified significance
level is controlled when the decision rules defined above
are adhered to [35].
Additionally to the hypothesis testing approach, the pri-
mary endpoint will be analysed by applying Bayesian
methods. Starting with the uniform distribution for the
tolerability rate as prior distribution for the preceding
trial OVAR-IMRT-01 [26,30,31], the posterior distribu-
tion of this trial is derived which serves as prior distribu-
tion for the current study OVAR-IMRT-02. Employing
the results of OVAR-IMRT-02 leads to an updated pos-
terior distribution for the tolerability rate from which
Bayesian inference on p will be derived.
The secondary outcome variables will be evaluated by
application of methods of descriptive data analysis.
Appropriate measures of the empirical distribution as
well as 95% confidence intervals will be calculated. All
statistical analyses will be performed with SAS version
9.0 or higher.
Investigation schedule
Therapy Indication
For each patient, the oncologic treatment concept after
diagnosis is based on a tumor board review, following
approved standard therapies and current guidelines.
Consent of the colleagues from gynaecology, internal
medicine and radiation oncology are obligatory.
Pre-therapeutic examinations
A complete staging is performed before surgery and/or
chemotherapy, including abdominopelvic CT scan or
MRI, radiography or CT scan of the chest, liver sono-
graphy, pelvic examination, transvaginal sonography,
CA-125. After completion of chemotherapy, the com-
plete remission is assessed by pelvic examination, trans-
vaginal sonography and measure of CA-125.
The baseline visit is performed at study enrollment,
after obtaining of the written consent of the patient. It
includes blood test, clinical examination and quality of
life questionnaire (EORTC-QLQ30).
Radiotherapy-planning
After immobilisation in a vacuum mattress and a scotch
cast head mask (arms above the head) the patients
undergo a native and contrast enhanced abdomino-
pelvic computed tomography (optionally with 4D respira-
tory triggering). This CT scan is used for the restaging
and for the radiation planning.
The clinical target volume (CTV) includes the whole
peritoneal cavity extending from diaphragm to douglas
cavity, the liver surface, and the pelvic and para-aortic
node regions. The planning target volume (PTV)
encompasses an axial margin of 1.5 cm around the CTV
(2.5 cm in the cranial direction). Organs at risk are
kidneys, liver (except the 1 cm-outer border), lungs,
bones (vertebral bodies and pelvic bones), hear and
spinal cord.
A dose of 30.0 Gy is prescribed to the median of the
PTV. Inverse radiation planning is performed according
to the national DIN norm and international recommen-
dations (ICRU 50 Report 1999). The goal of optimiza-
tion is to deliver a dose distribution in the PTV as
homogeneous as possible in spite of maximal sparing of
OARs with a high priority on liver, kidney and bone
marrow. Tolerated maximum doses to OARs are not to
exceed the TD5/5 for each organ (31).
Radiation therapy
Irradiation is applied as helical intensity-modulated
radiation therapy (IMRT) using a tomotherapy device
(Madison, Wisconsin, USA) with 6 MeV photons. Con-
trol of positioning accuracy is performed daily with the
integrated megavoltage computed tomography for
tomotherapy (MV-CT scan, 3.5 MV).
Duration of treatment
The delay between the last chemotherapy and the onset
of radiation should not exceed 10 weeks. The duration
of the treatment planning is estimated about 2 or
3 weeks. The duration of radiotherapy is 4 weeks (20
fractions). The overall daily treatment time is expected
to be about 15 to 20 minutes with a mean daily “time
on table” of about half an hour.
Treatment schedule
The radiotherapy is performed on an out-patient basis
with the possibility of hospital admission if required.
Monitoring during treatment
Patients are evaluated weekly during radiotherapy.
Antiemetic and antidiarrheal medications are prescribed
as required. Blood count is assessed twice weekly. Toxi-
cities are graded according to the National Cancer Insti-
tute Common Toxicity Criteria version 3.0. The quality
of life is assessed at the last treatment fraction using
EORTC-QLQ30 questionnaire. The documentation of
acute hematologic, genito-urinary and gastro-intestinal
acute toxicities is especially relevant.
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Follow-up visits are scheduled in addition to the stan-
dard gynaecology follow-up program at 6 weeks, 3, 6, 9,
12, 15, 18, 24, 30 and 36 months, respectively, after
completion of radiotherapy. Each visit includes blood
test, CA-125, pelvic examination, transvaginal ultra-
sound, recording of adverse events and assessment of
quality of life (questionnaire EORTC-QLQ30). The doc-
umentation of late genito-urinary and gastro-intestinal
toxicities (such as bowel obstruction) is especially
relevant. Additionally, a contrast-enhanced abdomino-
pelvic CT scan or MRI will be performed at 6, 12 und
24 months, respectively.
Duration of the study
The primary objective of the study is to prove the good
treatment tolerance, defined as non-occurrence of CTC
grade 4 toxicities during radiotherapy and till 6 weeks
after its completion. To assess the primary endpoint, the
final study visit will be 6 weeks after the last patient
completed the radiotherapy. The study ends three years
after the last patient was treated. Recruitment of the
patients is planned over a time period of 36 months; fol-
low-up duration will be 36 months.
Data Handling, Storage and Archiving of Date
All findings including clinical and laboratory data will be
documented by the investigator or an authorized mem-
ber of the study team in the subject’s medical record
and in the CRF. The data will be stored and archived
according to the §13 of the German GCP-Regulation
and §28 c of the German X-Ray Regulation (StrlSchV)
for at least 30 years after the trial termination.
Ethics, informed consent and safety
The final protocol was approved by the ethics commit-
tee of the University of Heidelberg, Heidelberg,
Germany (Nr: S-353/2008). Additionally, a positive vote
of the Bundesamt für Strahlenschutz (BfS) has been
obtained. This study complies with the Helsinki Declara-
tion in its recent German version. The trial will also be
carried out in keeping with local legal and regulatory
requirements. The ClinicalTrials.gov Protocol ID is
NCT01180504.
All severe adverse events have to be reported immedi-
ately to the principal investigator. In addition, side
effects and patient safety will be monitored by an inde-
pendent data safety monitoring committee (DMC), com-
posed of one radio oncologist, one gynaecologist and
one statistician. In case of frequent or particularly ser-
i o u sa d v e r s ee v e n t s ,t h e nt h eD M Cw o u l dh a v et oc o n -
sider termination of the study. This evaluation has to be
made in consideration of risk/benefit. The DMC will
meet on a regular basis.
Discussion
The prognosis for patients with advanced FIGO stage III
epithelial ovarian cancer remains poor despite the aggres-
sive standard treatment, consisting of maximal cytoreduc-
tive chemotherapy and platinum-based chemotherapy.
The median time to recurrence, which occurs mostly
intraperitoneally, is less than 2 years, with a 5-years survi-
val rate of -20-25% [1-5].
Ovarian cancer is a radiosensitive tumor, so that WAR
as a consolidation therapy would appear to be a logical
strategy. WAR used to be the standard treatment after
surgery before the chemotherapy era. However, WAR
has been almost totally excluded from the treatment of
ovarian cancer during the past decade because of its
high toxicity [9,10]. Since toxicity can be managed by
modern radiotherapy technique (IMRT), WAR provides
a new promising option in the consolidation treatment
of ovarian carcinoma in patients with complete patholo-
gic remission after adjuvant chemotherapy [26,30].
In our previous phase-I study, we showed for the first
time the clinical feasibility of intensity-modulated WAR
in combination with modern chemotherapy and surgery
[31]. It rendered an excellent coverage of the entire peri-
toneal cavity including frequent sites of abdominal recur-
rence like the liver capsule and the diaphragm as well as
of the pelvic- and para-aortic node regions. An effective
sparing of liver, kidneys and bone marrow allowed deli-
vering the treatment as planned, with a high compliance
of patients.
The current phase-II succeeds to the phase-I study to
demonstrate the good tolerability of the treatment
(defined as non-occurrence of CTC grade 4 acute toxici-
ties) and to further evaluate toxicity and outcome of this
new treatment.
In the previous phase-I study, small bowel obstruction
due to adhesions occurred in 3 of 10 patients, 2.5, 3 and
13 months respectively after radiotherapy. The exact role
played by radiotherapy in the development of peritoneal
adhesions remains unclear and further studies are needed
to evaluate this problem. Risk factors for late bowel toxi-
city are suggested by literature: dose escalation with a
total abdominal dose over 30 Gy, pelvic-boost and/or
para-aortic boost and previous second-look laparotomy
are associated with a significant increase in small bowel
obstruction [23,32,33]. Given that the addition of pelvic
boost treatment is not clearly beneficial in the literature;
the routine use of a pelvic boost in consolidation WAR
should be questioned [23]. With respect to these argu-
ments, this study was designed with careful attention to
keeping the risk for late bowel toxicity as low as possible
and bowel adverse events will be monitored accurately.
Intensity-modulated WAR could offer a new therapeu-
tic option for consolidation treatment of advanced ovar-
ian carcinoma after adjuvant chemotherapy in selected
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studies are needed to draw firm conclusions regarding
the value of consolidation radiotherapy in the multimo-
dal treatment of ovarian carcinoma, including immuno-
logic and biologic therapies in the future.
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